# A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

> **NCT03381833** · PHASE2 · TERMINATED · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 84 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **DRUG:** LJPC-401
- **DRUG:** LJPC-401

## Key facts

- **NCT ID:** NCT03381833
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-30
- **Primary completion:** 2019-12-03
- **Final completion:** 2020-01-14
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Terminated early for lack of efficacy as determined by interim endpoint analyses
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381833, "A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03381833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*